Work is under way at Southwest Research Institute on a $1.5 million, three-year project awarded by the Defense Advanced Research Projects Agency to develop novel technologies for depositing thin films.
Berkeley Lab researchers have shown that tiny bubbles carrying hyperpolarized xenon gas hold big promise for NMR (nuclear magnetic resonance) and its sister technology, MRI (Magnetic Resonance Imaging), as these xenon carriers can be used to detect the presence and spatial distribution of specific molecules with far greater sensitivity than conventional NMR/MRI.
The new material consists of multiple identical pieces of grossly warped graphene, each containing exactly 80 carbon atoms joined together in a network of 26 rings, with 30 hydrogen atoms decorating the rim.
Micro and nanotechnologies (MNT) for space applications will be the theme of this important meeting. It will take place in the new Swiss Tech Convention Center on 10-13 June 2014 and will host members from national delegations, space agencies, space and MNT industries, research centrers and universities.
A fundamental advance in measurement capabilities that could save semiconductor manufacturers billions of dollars annually has earned a 2013 R+D 100 Award for its National Institute of Standards and Technology (NIST) inventors.
In a pellet of glass the size of an apple seed, University of Michigan engineering researchers have packed seven devices that together could potentially provide navigation in the absence of the satellite-based Global Positioning System (GPS.)
Researchers report on a new way of sculpting tailor-made fluid flows by placing microscale pillars in microfluidic channels. The method could allow clinicians to better separate white blood cells in a sample, increase mixing in industrial applications, and more quickly perform lab-on-a-chip-type operations.
Better diagnosis and treatment of cancer could hinge on the ability to rapidly map out networks of dozens of molecules in individual tumor cells. New research from the University of Washington offers a more comprehensive way of analyzing a single cell's unique behavior and could reveal patterns that indicate why a cell will or will not become malignant.
Researchers have shown that they can use a gold nanoparticle tumor necrosis factor-alpha system to enhance the effects of either thermal therapy or cryosurgery. Moreover, they demonstrated that they can use standard magnetic resonance imaging technology to visualize tumor destruction.
Activating the body's immune system to attack cancer and prevent it from recurring is one of the Holy Grails of cancer research because of its ability to specifically target cancer and to search almost anywhere in the body for rogue tumors. While the field has made some progress, and immune therapy for malignant melanoma and prostate cancer is proving its value in the treatment of human disease, it appears that no one general approach is going to work in all types of cancer. Two recent papers show how nanoparticles could become important tools for stimulating the immune system to respond to cancer.
Investigators at the University of Florida have developed what they are calling a 'DNA nanotrain' that fast-tracks its payload of cancer-fighting drugs and bioimaging agents to tumor cells deep within the body. These nanotrains have the potential to cost-effectively deliver high doses of drugs to precisely targeted cancers using biocompatible materials that fall apart into non-toxic components once their payload is delivered.
Herceptin and camptothecin are both powerful anticancer agents with key characteristics that limit their effectiveness in treating cancer. Patients treated with Herceptin, a monoclonal antibody that targets a growth promoting factor common to breast cancers, often relapse as their tumors become resistant to the drug. Overcoming camptotheci's toxicity and low solubility represent major therapeutic challenges. Now, researchers have used nanotechnology to combine the two into what so far appears to be a highly effective drug for treating aggressive breast cancer.